54 Chapter 3 19. Moerman N, van Dam FSAM, Muller MJ, Oosting H. The Amsterdam Preoperative Anxiety and Information Scale (APAIS). Anesth Analg. 1994;82:445-51. 20. Anovulation and wish to conceive: Dutch Society of Obstetrics and Gynaecology; 2004 [Available from: https://www.nvog.nl/wp-content/uploads/2017/12/Anovulatie-en-kinderwens-2.0-12-11-2004.pdf. 21. Basic fertility work-up: Dutch Society of Obstetrics and Gynaecology; 2015 [Available from: https://richtlijnendatabase.nl/richtlijn/orienterend_fertiliteitsonderzoek_ofo/startpagina_ orienterend_fertilitietsonderzoek.html. 22. Unexplained infertility: Dutch Society for Obstetrics and Gynaecology; 2020 [Available from: https://richtlijnendatabase.nl/richtlijn/onverklaarde_subfertiliteit/startpagina_-_onverklaarde_subfertiliteit.html. 23. Hunault CC, Laven JS, van Rooij IA, Eijkemans MJ, te Velde ER, Habbema JD. Prospective validation of two models predicting pregnancy leading to live birth among untreated subfertile couples. Hum Reprod. 2005;20(6):1636-41. 24. Bouwmans C. Manual iMTA Productivity Cost Questionnaire (iPCQ) 2013 [Available from: www.imta.nl. 25. Kanters TA, Bouwmans CAM, van der Linden N, Tan SS, Hakkaart-van Roijen L. Update of the Dutch manual for costing studies in health care. PLoS One. 2017;12(11):e0187477. 26. NICE. The guidlines manual: Assessing cost effectiveness 2012 [Available from: https:// www.nice.org.uk/article/pmg6/chapter/7-assessing-cost-effectiveness#economic-evidence-and-guideline-recommendations. 27. ICH. Good Clinical Practice (GCP) https://www.ich.org/: International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human use; 2016 [ 28. WHO Trial Registration Data Set. Version 1.3.1: World Health Organization; [Available from: https://www.who.int/clinical-trials-registry-platform/network/who-data-set. 29. HFEA. Fertility treatment 2019: trends and figures 2021 [UK statistics for IVF and DI treatment, storage and donation]. Available from: https://www.hfea.gov.uk/about-us/publications/research-and-data/fertility-treatment-2019-trends-and-figures/. 30. SART. Preliminary National Summary Report 2019 2022 [Available from: https://www.sartcorsonline.com/rptCSR_PublicMultYear.aspx?ClinicPKID=0. 31. DeCherney AH, Kort H, Barney JB, DeVore GR. Increased pregnancy rate with oil-soluble hysterosalpingography dye. Fertil Steril. 1980;33(4):407-10. 32. Alper MM, Garner PR, Spence JEH, Quarrington AM. Pregnancy rates after hysterosalpingography with oil- and water-soluble contrast media. Obstetrics and Gynecology. 1986;68(1):69. 33. Schwabe MG, Shapiro SS, Haning RV. Hysterosalpingography with oil contrast medium enhances fertility in patients with infertility of unknown etiology. Fertil Steril. 1983;40(5):6046. 34. Steiner AZ, Meyere WR, Clark RL, Hartmann KE. Oil-soluble contrast during hysterosalpingography in women with proven tubal patency. Obstetrics and Gynecology. 2003;101:10913. 35. Infertility: Dutch Society of Obstetrics and Gynaecology; 2010 [Available from: https:// www.nvog.nl/wp-content/uploads/2018/02/Subfertiliteit-landelijke-netwerkrichtlijn-1.0-20-05-2011.pdf. 36. van Welie N, Pham CT, van Rijswijk J, Dreyer K, Verhoeve HR, Hoek A, et al. The long-term costs and effects of tubal flushing with oil-based versus water-based contrast during hysterosalpingography. Reprod Biomed Online. 2021;42(1):150-7.
RkJQdWJsaXNoZXIy MTk4NDMw